What it's for (Indications)
- Fusidic acid is an antimicrobial agent primarily indicated for the treatment of bacterial infections caused by susceptible organisms, most notably *Staphylococcus aureus*, including methicillin-resistant *S.
- aureus* (MRSA) strains in certain contexts.
- Its applications vary based on the route of administration.
- Topically, it is used for the treatment of primary and secondary bacterial skin infections such as impetigo, folliculitis, furunculosis, paronychia, and erythrasma.
- Ophthalmic formulations are prescribed for bacterial conjunctivitis.
- Systemically (oral or intravenous), fusidic acid is reserved for more serious or deep-seated infections, including osteomyelitis, septic arthritis, endocarditis, and severe skin and soft tissue infections, often in combination with other antibacterial agents to prevent the development of resistance and to broaden the spectrum of coverage.
- Its efficacy against a range of Gram-positive bacteria makes it a valuable option in specific clinical scenarios where susceptibility is confirmed.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of fusidic acid is highly dependent on the formulation, the specific infection being treated, the patient's age and weight, and renal/hepatic function. For topical cream or ointment, it is typically applied to the affected area two to three times daily for a period not exceeding 7 to 10 days, or as directed by a physician. For ophthalmic gel or drops, a single drop is usually instilled into the conjunctival sac twice daily for seven days. Systemic dosages (oral or intravenous) are variable. For adults, typical oral doses range from 250 mg to 500 mg every 8 to 12 hours, often administered with food to minimize gastrointestinal upset. Intravenous administration protocols are tailored to the severity of the infection and patient characteristics, frequently involving infusions of 500 mg to 1000 mg every 8 to 12 hours. Due to the risk of resistance, systemic fusidic acid is commonly used in combination with other antibiotics, and treatment duration is determined by clinical response and microbiological data. Dose adjustments may be necessary in patients with severe hepatic impairment. |
Safety & Warnings
Common Side Effects
- Fusidic acid can induce a range of side effects, which vary depending on the route of administration.
- Topically, common adverse reactions include mild irritation, burning, stinging, itching, rash, and contact dermatitis at the application site.
- Ophthalmic use may lead to transient blurred vision, stinging or irritation, conjunctival hyperaemia, or eyelid oedema.
- Systemic administration is associated with more frequent and potentially more serious adverse events.
- Gastrointestinal disturbances such as nausea, vomiting, diarrhea, abdominal pain, and dyspepsia are common.
- Skin rashes, pruritus, and urticaria have been reported.
- A significant concern with systemic fusidic acid is hepatobiliary dysfunction, manifesting as reversible cholestatic jaundice, elevation of liver enzymes (e.
- g.
- , ALT, AST, alkaline phosphatase), and hyperbilirubinemia, particularly with high doses, prolonged treatment, or in susceptible individuals.
- Rarely, more severe systemic reactions, including anaphylaxis, angioedema, and haematological abnormalities (e.
- g.
- , leukopenia, thrombocytopenia), have been observed.
- Patients should be advised to report any persistent or worsening adverse effects to their healthcare provider.
Serious Warnings
- Black Box Warning: While fusidic acid does not carry a formal FDA Black Box Warning, clinicians and patients must be made aware of critical safety information, which warrants the functional equivalent of a 'Serious Warnings' section due to its high-risk profile in certain clinical contexts. **Serious Warnings:** Systemic fusidic acid therapy is associated with a severe and potentially fatal drug interaction with HMG-CoA reductase inhibitors (statins). Concomitant administration of systemic fusidic acid with any statin is absolutely contraindicated. This combination significantly increases statin plasma concentrations, leading to a drastically elevated risk of serious adverse events including severe myopathy, rhabdomyolysis, and acute kidney injury. Patients requiring systemic fusidic acid must discontinue statin therapy for the duration of the fusidic acid treatment course and for a period thereafter, as determined by the treating physician, to allow for statin washout. Furthermore, systemic fusidic acid poses a considerable risk of hepatobiliary dysfunction. Cases of reversible cholestatic jaundice, significant elevation of liver enzymes (transaminases), and hyperbilirubinemia have been reported, particularly with high doses, prolonged treatment, or in patients with pre-existing hepatic impairment or biliary obstruction. Regular and vigilant monitoring of liver function tests (LFTs) is imperative for all patients receiving systemic fusidic acid. In neonates, especially premature infants, systemic fusidic acid must be used with extreme caution due to the potential for increased unconjugated bilirubin levels, raising concerns about the risk of kernicterus. This effect is thought to be mediated by fusidic acid's ability to displace bilirubin from albumin binding sites. Careful risk-benefit assessment and close monitoring of bilirubin levels are essential in this vulnerable population. Patients should be counseled on the signs and symptoms of myopathy, rhabdomyolysis, and liver dysfunction and instructed to seek immediate medical attention if they experience muscle pain, weakness, dark urine, yellowing of the skin or eyes, or severe abdominal pain.
- Systemic fusidic acid requires careful clinical management due to its potential for significant drug interactions and hepatotoxicity.
- Patients with pre-existing hepatic impairment or biliary obstruction should be treated with extreme caution, and liver function should be monitored rigorously throughout systemic therapy, as fusidic acid is extensively metabolized by the liver and excreted in bile.
- Reversible cholestatic jaundice and elevated liver enzymes are known risks, especially with high doses or prolonged treatment.
- Concomitant use of systemic fusidic acid with HMG-CoA reductase inhibitors (statins) is contraindicated due to the significantly increased risk of severe myopathy, rhabdomyolysis, and acute kidney injury resulting from elevated statin concentrations.
- Statin therapy must be discontinued during fusidic acid treatment.
- Prolonged or widespread topical use of fusidic acid may lead to the selection and overgrowth of non-susceptible organisms, including fungi.
- Hypersensitivity reactions, ranging from skin rashes to severe anaphylaxis, can occur; the medication should be discontinued immediately if such reactions develop.
- Systemic use in neonates, particularly premature infants, warrants extreme caution due to the risk of hyperbilirubinemia and kernicterus, as fusidic acid can displace bilirubin from albumin binding sites.
- Resistance development is a known issue, especially when fusidic acid is used as monotherapy for systemic infections, necessitating its frequent use in combination with other antibiotics.
How it Works (Mechanism of Action)
Fusidic acid exerts its antibacterial effect by inhibiting bacterial protein synthesis. It belongs to the fusidanin class of antibiotics and acts by specifically targeting the bacterial elongation factor G (EF-G). Fusidic acid binds to EF-G in complex with GTP, preventing its dissociation from the bacterial ribosome after GDP hydrolysis. This arrests the translocation step of protein synthesis, effectively stalling the ribosome and preventing the synthesis of new proteins essential for bacterial growth and replication. This mechanism is distinct from other classes of antibiotics that target protein synthesis, contributing to a lower incidence of cross-resistance. Fusidic acid demonstrates potent activity primarily against Gram-positive bacteria, particularly *Staphylococcus aureus*, including some strains of methicillin-resistant *S. aureus* (MRSA), and other staphylococcal species, as well as some streptococci and corynebacteria. It is generally considered bacteriostatic at therapeutic concentrations, but can be bactericidal at higher concentrations against highly susceptible organisms.